Literature DB >> 12857933

A naturally occurring substitution in human immunodeficiency virus Tat increases expression of the viral genome.

Syed M Reza1, Lin-Ming Shen, Rupa Mukhopadhyay, Mihaela Rosetti, Tsafi Pe'ery, Michael B Mathews.   

Abstract

A natural amino acid substitution in the human immunodeficiency virus type 1 (HIV-1) transcriptional activator Tat increases its activity and compensates for deleterious mutations elsewhere in the Tat protein. Substitution of asparagine for threonine 23 increases Tat transactivation of the HIV-1 promoter and the binding of Tat to the cellular kinase positive transcription elongation factor b (P-TEFb). Of nine other position 23 mutations tested, only the serine substitution retained wild-type activity. Correspondingly, asparagine is the most frequent amino acid at this position in HIV-1 isolates, followed by threonine and serine. Asparagine is prevalent in Tat proteins of viruses in clades A, C, and D, which are major etiologic agents of AIDS. We suggest that selection for asparagine in position 23 confers an advantage to the virus, since it can compensate for deleterious mutations in Tat. It may also support the replication of otherwise less fit drug-resistant viruses and permit the emergence of virulent strains.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857933      PMCID: PMC165250          DOI: 10.1128/jvi.77.15.8602-8606.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

Review 1.  P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.

Authors:  D H Price
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 2.  Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Authors:  T Pierson; J McArthur; R F Siliciano
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents.

Authors:  J M Péloponèse; Y Collette; C Grégoire; C Bailly; D Campèse; E F Meurs; D Olive; E P Loret
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

Review 4.  Using HIV-1 sequence variability to explore virus biology.

Authors:  K M McGrath; N G Hoffman; W Resch; J A Nelson; R Swanstrom
Journal:  Virus Res       Date:  2001-08       Impact factor: 3.303

5.  Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

Authors:  G Bleiber; M Munoz; A Ciuffi; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis.

Authors:  R A Boykins; R Mahieux; U T Shankavaram; Y S Gho; S F Lee; I K Hewlett; L M Wahl; H K Kleinman; J N Brady; K M Yamada; S Dhawan
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

7.  Human and rodent transcription elongation factor P-TEFb: interactions with human immunodeficiency virus type 1 tat and carboxy-terminal domain substrate.

Authors:  Y Ramanathan; S M Reza; T M Young; M B Mathews; T Pe'ery
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 8.  Tackling Tat.

Authors:  J Karn
Journal:  J Mol Biol       Date:  1999-10-22       Impact factor: 5.469

9.  CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA.

Authors:  M E Garber; T P Mayall; E M Suess; J Meisenhelder; N E Thompson; K A Jones
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

10.  Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

Authors:  P Mooij; W M Bogers; H Oostermeijer; W Koornstra; P J Ten Haaft; B E Verstrepen; G Van Der Auwera; J L Heeney
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

View more
  10 in total

1.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency.

Authors:  Mudit Tyagi; Jonathan Karn
Journal:  EMBO J       Date:  2007-11-15       Impact factor: 11.598

3.  p53-derived host restriction of HIV-1 replication by protein kinase R-mediated Tat phosphorylation and inactivation.

Authors:  Cheol-Hee Yoon; Sang-Yoon Kim; Se Eun Byeon; Yideul Jeong; Jinjoo Lee; Kwang Pyo Kim; Jinseu Park; Yong-Soo Bae
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

4.  Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.

Authors:  Yan Desfosses; Mayra Solis; Qiang Sun; Nathalie Grandvaux; Carine Van Lint; Arsene Burny; Anne Gatignol; Mark A Wainberg; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction.

Authors:  Mudit Tyagi; Richard John Pearson; Jonathan Karn
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

6.  Site-specific amino acid frequency, fitness and the mutational landscape model of adaptation in human immunodeficiency virus type 1.

Authors:  Jack da Silva
Journal:  Genetics       Date:  2006-07-18       Impact factor: 4.562

7.  HIV-1 clade promoters strongly influence spatial and temporal dynamics of viral replication in vivo.

Authors:  Mireille Centlivre; Peter Sommer; Marie Michel; Raphaël Ho Tsong Fang; Sandrine Gofflo; Jenny Valladeau; Nathalie Schmitt; Françoise Thierry; Bruno Hurtrel; Simon Wain-Hobson; Monica Sala
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

8.  Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness.

Authors:  Antoinette C van der Kuyl; Karolina Kozaczynska; Kevin K Ariën; Youssef Gali; Victoria R Balázs; Stefan J Dekker; Fokla Zorgdrager; Guido Vanham; Ben Berkhout; Marion Cornelissen
Journal:  Retrovirology       Date:  2010-07-20       Impact factor: 4.602

9.  Molecular and genetic characterization of natural HIV-1 Tat Exon-1 variants from North India and their functional implications.

Authors:  Larance Ronsard; Sneh Lata; Jyotsna Singh; Vishnampettai G Ramachandran; Shukla Das; Akhil C Banerjea
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

10.  Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures.

Authors:  Gregory C Antell; Will Dampier; Benjamas Aiamkitsumrit; Michael R Nonnemacher; Jeffrey M Jacobson; Vanessa Pirrone; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Gregory Schwartz; Uri Hershberg; Fred C Krebs; Brian Wigdahl
Journal:  Retrovirology       Date:  2016-05-03       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.